Pair Name	Cordycepin, Cisplatin
Disease Info	[ICD-11: 2B51]	Osteosarcoma		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Phosphorylation	PRKAA1	hsa5562
	Down-regulation	Phosphorylation	RPS6KB1	hsa6198
In Vitro Model	U2OS	Osteosarcoma	Homo sapiens (Human)	CVCL_0042
	143B	Osteosarcoma	Homo sapiens (Human)	CVCL_2270
In Vivo Model	1×10⁶ suspended 143B cells in 20 µL were injected into the proximal tibia through the anterior tuberosity.
Result	This study provides comprehensive evidence that cordycepin inhibits osteosarcoma cell growth and invasion and induces osteosarcoma cell apoptosis by activating AMPK and inhibiting the AKT/mTOR signaling pathway and enhances the sensitivity of osteosarcoma cells to cisplatin, suggesting that cordycepin is a promising treatment for osteosarcoma.

Pair Name	Cordycepin, Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Up-regulation	Phosphorylation	PRKAA1	hsa5562
	Up-regulation	Expression	PSMD9	hsa5715
	Down-regulation	Phosphorylation	RPS6	hsa6194
	Down-regulation	Phosphorylation	RPS6KB1	hsa6198
	Up-regulation	Phosphorylation	TP53	hsa7157
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
In Vivo Model	A total of 2×10⁶ A549 or A549DDP cells were suspended in 100 μl of normal saline and subcutaneously injected into unilateral axillary fossae of BALB/c nude mice (4 weeks old, n = 5 per group).
Result	Our results suggested that Cor in combination with DDP could be an additional therapeutic option for the treatment of DDP-resistant NSCLC.